Incyte INCY Business Segments — Net Income
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Incyte in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Incyte’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Incyte's business segments — net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Incyte's business segments — net income?
- Incyte (INCY) reported business segments — net income of $303.33M in Q1 2026.
- How has Incyte's business segments — net income changed year-over-year?
- Incyte's business segments — net income increased by 91.7% year-over-year, from $158.2M to $303.33M.
- What is the long-term trend for Incyte's business segments — net income?
- Over 3 years (2022 to 2025), Incyte's business segments — net income has grown at a 55.7% compound annual growth rate (CAGR), from $340.66M to $1.29B.
- What does business segments — net income mean?
- This represents the total profit generated by the primary business segment after accounting for all operating expenses, research and development costs, and collaboration-related financial adjustments. It serves as the bottom-line performance indicator for the company's core pharmaceutical discovery and commercialization activities.